Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ginger Bryant

Orthopaedic Surgery Birmingham, AL Medical Doctor

NPI 1285688762 CMS profile 103906

1813 6Th Ave S, Birmingham, AL 35233

Open in the dashboard

General payments

$208,689

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ginger Bryant of Birmingham, AL is reported in the CMS Open Payments database as having received $208,689 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,540 6
2024 General $88 1
2023 General $541 2
2022 General $53,510 25
2021 General $65,787 52
2020 General $61,134 30
2019 General $26,089 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ginger Bryant
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Ginger Bryant were reported at $1,540. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Ginger Bryant Orthopaedic Surgery median Middle half National median
2019 $26,089 $644 $140–$2,844 $163
2020 $61,134 $312 $75–$1,860 $114
2021 $65,787 $520 $117–$2,495 $132
2022 $53,510 $598 $128–$2,731 $149
2023 $541 $461 $128–$2,264 $160
2024 $88 $497 $134–$2,475 $164
2025 $1,540 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $207,296 123 payments
  2. Alpha Orthopedic Systems $1,207 2 payments
  3. IlluminOss Medical, Inc. $98 1 payment
  4. Zimmer Biomet Holdings, Inc. $89 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $187,611 42 payments
  2. Travel and Lodging $17,989 54 payments
  3. Food and Beverage $1,889 30 payments
  4. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. T2 Trauma & Extremeties $86,825 39 payments
  2. AXSOS Trauma & Extremeties $71,771 31 payments
  3. AXSOS Trauma & Extremeties $50,779 18 payments
  4. T2 Trauma & Extremeties $50,679 19 payments
  5. VARIAX $47,008 25 payments
  6. GAMMA Trauma & Extremeties $46,310 17 payments
  7. GAMMA Trauma & Extremeties $38,875 19 payments
  8. PRO $30,591 26 payments
  9. HOFFMANN $27,547 15 payments
  10. TRIATHLON $21,598 8 payments
  11. Other $79,262 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

47

Median for Orthopedic Surgery: 203

Drug cost

$398

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 24 $262
Meloxicam Generic 23 $135

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$39,206

Of which drugs: $230

Medicare patients

142

Average age 77

Services billed

1,045

88 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 43%
Chronic kidney disease 24%
Ischemic heart disease 23%
Depression 23%
Atrial fibrillation 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 35 47 $171
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 720 $59

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record